Efficacy and safety of a new intravenous immunoglobulin (Panzyga(®)) in chronic immune thrombocytopenia

OBJECTIVES: To assess the efficacy and safety of intravenous immunoglobulin (IVIG) 10% (Panzyga(®)), a novel human normal IVIG 10%, in patients with chronic immune thrombocytopenia (ITP). BACKGROUND: First‐line treatment options in ITP include IVIGs. METHODS: In this prospective, open‐label, non‐con...

Descripción completa

Detalles Bibliográficos
Autores principales: Arbach, O., Taumberger, A. B., Wietek, S., Cervinek, L., Salama, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850321/
https://www.ncbi.nlm.nih.gov/pubmed/30687970
http://dx.doi.org/10.1111/tme.12573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850321/
https://www.ncbi.nlm.nih.gov/pubmed/30687970
http://dx.doi.org/10.1111/tme.12573

Ejemplares similares